30 results
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
PWS with a birth incidence ranging from 1:15,000 to 1:25,000. In addition, according to an abstract published in the Journal of Endocrine Society
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
:15,000 to 1:25,000. In addition, according to an abstract published in the Journal of Endocrine Society, a 2020 review of medical claims provided
424B5
SLNO
Soleno Therapeutics Inc
27 Sep 23
Prospectus supplement for primary offering
5:26pm
, according to an abstract published in the Journal of Endocrine Society, a 2020 review of medical claims provided by IQVIA Health Plan and CMS
8-K
EX-99.1
zis16 zcc
10 May 22
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
4:01pm
424B5
pz8wubd 2f7go
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
shrrlg05awd hjo
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
edh7zue2 8ekrevk
5 May 21
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:01pm
424B5
56dcbelq mg6
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
riq311
23 Jun 20
Prospectus supplement for primary offering
4:06pm